How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat type 2 diabetes and obesity.

Further research is needed to better understand their use. The addition of glucagon-like peptide-1 receptor agonists to progestin therapy may help reduce endometrial cancer risk among certain ...

United Laboratories’ candidate, dubbed UBT251, belongs to a class of weight loss drugs that potentially elicit greater weight loss than the popular and currently available glucagon-like peptide-1 ...

Study: Abilities of Rare Sugar Members to Release Glucagon-like Peptide-1 and Suppress Food Intake in Mice. Image Credit: Love Employee / Shutterstock Study findings revealed that three rare sugar ...

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...